Colgate-Palmolive’s 2022 Global Productivity Initiative should result in annualized pre-tax savings in the range of $90m to $100m, the New York firm said in its fourth quarter earnings presentation on 28 January. The Filorga impairment charge reflects the pandemic’s impact on duty-free and travel retail channels since Colgate acquired the France-based, premium skin-care brand in 2019 for nearly $1.7bn.
Colgate-Palmolive response to today’s “volatile” operating environment is a plan for increased pricing and advertising, as well as a new productivity initiative that should result in annualized pre-tax savings in the range of $90m to $100m, the New York-based firm says.
Colgate’s 2022 Global Productivity Initiative will accelerate changes to the firm’s operating structure so resources can be reallocated to strategic...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
CEO Sue Nabi says Coty has created a “multi-functional, stand-alone organization” within its Consumer Beauty business to drive rapid-fire innovation. In a 20 August presentation, Nabi said the firm’s innovation pipeline undergirds its fiscal 2025 outlook of 6%-8% growth.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
